Compare IAC/Interactivecorp (PPLI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Sanofi SA — how do they compare? IAC/Interactivecorp trades at $40.98 (market cap $3.05B), while Sanofi SA trades at $40.05 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 31.2× IAC/Interactivecorp's market cap, and Sanofi SA pays a 6.01% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Sanofi SA for 94 Days on average.
| PPLI | SNY | |
|---|---|---|
Market Cap | $3.05B | $95.18B |
Volume | 931,019 | 2,995,646 |
Sector | Media | Health |
52-Week High | $47.62 | $52.34 |
52-Week Low | $31.52 | $39.51 |
Typical Hold Time | 79 Days | 94 Days |
Enterprise Value | $3.53B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.94, up 0.86% with bullish technical signals and strong analyst support (71% buy ratings). The stock shows mixed fundamentals with a low P/E of 6.92 and P/B of 0.6, but recent earnings volatility includes two misses and one beat. Recent MGM takeover speculation has driven significant price movement, with shares surging 11.3% following acquisition discussions.
Investment outlook balances attractive valuation metrics against operational challenges. The company faces revenue decline from $5.2B (2022) to $2.4B (2025) and negative net income in 2025, though 2026 projections show recovery. Key risks include media industry headwinds and execution uncertainty, while MGM deal potential offers upside catalyst.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
